Company Overview
Snapshot
Founded in March 2022 by Ravit Netzer and Adi Goldenzweig, Scala Biodesign operates with 11–50 employees. The company has raised $21.5 million across two funding rounds from six investors. In March 2026, Scala Biodesign secured an A Round of funding, with Grove Ventures and Bullet Ventures participating.
Business overview
Scala Biodesign develops advanced computational protein design solutions to tackle complex protein development challenges. Its core technology accelerates the development process, increases success rates, and reduces R&D efforts for proteins that require stringent activity, shelf-life, and safety standards. The company serves the pharmaceutical, chemical, diagnostics, and food sectors, operating within the Health Tech & Life Sciences sector, specifically focusing on Drugs Discovery & Development.
Strategic signal
In March 2026, Scala Biodesign announced an A Round of funding, highlighting significant investor confidence in its computational protein design platform. This capital infusion, with Grove Ventures as a lead investor, signals strong market validation for Scala's technology, which aims to drastically cut protein engineering timelines and enable new protein-based product development for global pharmaceutical and chemical corporations. The funding suggests an accelerated trajectory for the company's expansion and technological advancements.
Log in to access full profile ›Company Intelligence Q&A
- What is Scala Biodesign's primary focus?
- Scala Biodesign specializes in developing cutting-edge computational protein design solutions to address complex protein development challenges in various industries, including pharmaceutical, chemical, diagnostics, and food sectors.
- When was Scala Biodesign founded and by whom?
- Scala Biodesign was founded in March 2022 by Ravit Netzer and Adi Goldenzweig.
- What significant funding did Scala Biodesign receive in March 2026?
- In March 2026, Scala Biodesign secured an A Round of funding, with Grove Ventures and Bullet Ventures participating.
- What was a key milestone for Scala Biodesign in March 2022?
- In March 2022, Scala Biodesign received seed funding, with.
- What is the total capital raised by Scala Biodesign?
- Scala Biodesign has raised a total of $21.5 million across two funding rounds.